PALI
FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
PALI
Market-moving news on Palisade Bio (NASDAQ: PALI): filings, earnings, deals and other events, from REDFILED.